NCT04989816 - Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

June 16, 2023

Study Completion Date

February 28, 2024

Conditions

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG

Trastuzumab Deruxtecan

Trastuzumab deruxtecan (T-DXd) by intravenous infusion

Trial Locations (24)

100142

Research Site, Beijing

100191

Research Site, Beijing

110001

Research Site, Shenyang

200032

Research Site, Shanghai

210009

Research Site, Nanjing

215006

Research Site, Suzhou

230001

Research Site, Hefei

230031

Research Site, Hefei

250001

Research Site, Jinan

310003

Research Site, Hangzhou

310009

Research Site, Hangzhou

310020

Research Site, Hangzhou

330029

Research Site, Nanchang

350014

Research Site, Fuzhou

361003

Research Site, Xiamen

410008

Research Site, Changsha

430000

Research Site, Wuhan

450000

Research Site, Zhengzhou

450008

Research Site, Zhengzhou

510062

Research Site, Guangzhou

610042

Research Site, Chengdu

637000

Research Site, Nanchong

730030

Research Site, Lanzhou

750004

Research Site, Yinchuan